Fig. 3
Risk Factors for anti-EBV antibody levels in EBV seropositive participants aged > 1 year. Antibody levels were measured in serum of 8495 samples from 7150 EBV seropositive participants over 1 year of age and reported as median fluorescence intensities (MFI) which were log transformed. CD4 T cell and WHO HIV Disease Stage analyses included 307 samples from 273 participants and 338 samples from 268 participants, respectively. Linear mixed effects regression modelling was used to estimate the average difference in log transformed antibody levels between groups. For age treated as a continuous variable the estimate represents the average change in log transformed antibody levels for every one-year increase in age. For CD4 T cell count the estimates represent the average change in log transformed antibody levels for every 100-cell increase in CD4 T cell counts/mm3. Beta coefficients (•) and 95% confidence intervals (95% CI) (\({ \vdash }\)) are provided. All models included a random intercept and adjusted for all other co-factors. In adjusted models age was treated as continuous. For estimates refer to Additional file 1: Table S1. Other acronyms include: Human immunodeficiency virus (HIV), Kaposi’s sarcoma-associated herpesvirus (KSHV), World Health Organization (WHO)